Fortrea Holdings Inc. (FTRE) Stock Price & How to Invest

Fortrea Holdings is a global contract research organization (CRO) that runs clinical trials on behalf of pharmaceutical, biotech and medical device companies. It was separated from Labcorp in July 2023 and largely traces back to Covance, which Labcorp bought in 2015. Fortrea operates in roughly 90 countries and has three main pieces of business. Clinical pharmacology covers early-stage Phase I studies run in its own clinical units, where healthy volunteers or patients receive a drug for the first time. Full-service clinical development means managing Phase II to IV trials end to end, from site selection and patient recruitment through data management and regulatory submission. Functional service provision, or FSP, supplies dedicated staff who work inside a sponsor's own trial operations. Revenue comes from multi-year contracts, which is why backlog (about ~$7.8 billion at June 30, 2026, or nearly three years of revenue) is the number analysts watch most closely.

The investment picture is a turnaround that is visible in bookings but not yet in sales. After the spin-off, Fortrea struggled with the cost of exiting its transition services agreements with Labcorp, weak margins, and a ~$798 million goodwill impairment in the first half of 2025 that drove a full-year GAAP net loss of about ~$986 million. Full-year 2025 revenue was ~$2.72 billion, roughly flat on 2024, and adjusted EBITDA slipped to ~$190 million from ~$203 million. Under CEO Anshul Thakral, who took over in 2025, the company has cut SG&A, lowered restructuring and interest costs, paid down about ~$76 million of senior secured notes in Q4 2025, and posted four consecutive quarters of book-to-bill above 1.0x. In February 2026 it guided to ~$2.55 to ~$2.65 billion of 2026 revenue, then raised that in July to ~$2.62 to ~$2.69 billion, with adjusted EBITDA of ~$205 to ~$220 million. The open questions are whether new bookings convert into revenue growth (Q2 2026 revenue still fell ~4.5% year over year), whether margins can approach those of larger peers, and how quickly net debt of roughly ~$890 million can come down.

Revenue is still declining year over year, so the recovery case rests on bookings converting to growth rather than on results already delivered. Leverage of roughly ~4x adjusted EBITDA leaves less room for error than at peers such as IQVIA or ICON if a downturn in biotech funding or large-pharma budget cuts hits demand, and a weaker year could push the company back toward the covenant and refinancing questions that weighed on the stock in 2025. The finance function has had instability: the newly appointed CFO, Jason Knoblauch, was temporarily barred from serving by a July 2026 court order in a restrictive-covenant dispute with his former employer, leaving board member David Smith as interim CFO. Contract cancellations and delays, a normal feature of the CRO business, can shrink backlog quickly, and Fortrea has a shorter record as an independent company than its peers. The 2025 securities suit was dismissed in September 2026 but could still be appealed. Finally, after a move from ~$8.55 to ~$23 in a year, the share price already reflects a good part of the turnaround that management is describing, so results that only match guidance may not be enough to support it.

12 analysts publish price targets on FTRE, averaging $21.46 against a $22.49 price as of October 2026, or -4.6%. The published targets run from $13.50 to $26.00, a moderate spread, and the ratings split 7 buy, 4 hold, 2 sell. Over the last six months there have been 11 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full FTRE forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Fortrea Holdings Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Bookings recovery feeding the backlog. Fortrea reported a 1.06x book-to-bill in Q2 2026 and ~1.12x over the trailing twelve months, its fourth consecutive quarter above 1.0x. The most optimistic published target, $26.00, assumes this works close to its best case.

The case against. Revenue is still declining year over year, so the recovery case rests on bookings converting to growth rather than on results already delivered. The most pessimistic target, $13.50, is roughly what FTRE is worth if this bites instead.

Read the full bull and bear case on FTRE, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Fortrea Holdings Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$2.68 billion
• 2026 revenue guidance: ~$2.62 to ~$2.69 billion
• 2026 adjusted EBITDA guidance: ~$205 to ~$220 million
• Market cap: ~$2.2 billion (share price ~$22.75)
• Net debt: ~$890 million (about ~4x adjusted EBITDA)
• Backlog: ~$7.8 billion (June 30, 2026)

On GAAP numbers Fortrea is still loss-making (a ~$13 million net loss in Q2 2026 and roughly ~$85 million over the trailing twelve months), so the stock is usually valued on adjusted earnings, where the forward P/E is about ~24x, and on enterprise value. At roughly ~$3.1 billion, enterprise value is about ~14 to ~15x the midpoint of 2026 adjusted EBITDA guidance and a little over 1x sales. That multiple is not cheap for a company whose revenue is shrinking, which means the current price leans on margin expansion and a return to growth in 2027. For comparison, the stock traded near ~$850 to ~$880 million of market cap in late March and early April 2026, so most of the rerating has come from the Q2 beat and guidance raise. Post-earnings analyst targets in July 2026 ranged from roughly ~$20 (Deutsche Bank) to ~$26 (Truist), and the stock now sits near the upper half of that range. Fortrea's next quarterly report, for Q3 2026, is the next test of whether bookings are turning into revenue.

Other names that sit close to FTRE: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get FTRE exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so FTRE sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where FTRE fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Fortrea is a leveraged turnaround in clinical outsourcing whose bookings and cost cuts are improving, but whose revenue, GAAP profit and debt load still have to catch up with a share price that has more than doubled from its lows.

Whether FTRE is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is FTRE a buy or a sell?, and where the stock could go from here in the FTRE stock forecast.

For income investors, whether FTRE pays a dividend and how the payout looks is covered in does FTRE pay a dividend? And to weigh FTRE against a peer, read the full side-by-side comparisons: FTRE vs IQV and FTRE vs ICLR.